IPO TABLE: Neothetics launches; Juno, Bellicum seek big bucks; EyeGate cuts price range

The only drug developer to launch an initial public offering during the week of 17 to 21 November was Neothetics, a San Diego-based company targeting belly fat, but two new IPOs entered the queue with gut-busting fundraising targets.

The only drug developer to launch an initial public offering during the week of 17 to 21 November was Neothetics, a San Diego-based company targeting belly fat, but two new IPOs entered the queue with gut-busting fundraising targets.

Juno Therapeutics, a closely-watched player in the realm of chimeric antigen receptor T-cell (CAR-T) therapies for cancer, register an IPO...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category